



62 year old shopkeeper presented with complaints of swelling in the right side of the neck since 2 months & hoarseness of voice since 1 months#



EXAMINATION

ECOG PS: Good
Multiple fixed and hard lymph nodes were observed in the neck, specifically in levels 3 and 4



INVESTIGATIONS

- The patient underwent a CT scan of the thorax and neck indicating the presence of a mediastinal nodal mass involving multiple stations (Figure 1)
- An excision biopsy of a cervical node was performed, which revealed characteristics suggestive of metastatic small cell carcinoma
- MRI Brain - No intracranial metastases



DIAGNOSIS

- Extensive stage small cell carcinoma (M1b)



TREATMENT

- Patient was started on Tecentriq® with etoposide and carboplatin on 1st October 2021

Figure 1





Figure 2



Figure 3




OUTCOME

- ✔ The patient received four cycles of treatment with Tecentriq®, etoposide and carboplatin until January 18, 2022.
- ✔ After this treatment, a CT evaluation was conducted, which revealed a significant resolution of a mediastinal nodal mass, indicating a partial response to the treatment (Figure 2).
- ✔ Following this, the patient underwent thoracic radiation therapy (RT) and prophylactic cranial irradiation (PCI). The thoracic RT involved delivering a total dose of 30 gy over 10 fractions to the chest, while the PCI involved administering a total dose of 25 gy over 10 fractions to the brain.
- ✔ Post 4 months of maintenance, evaluation showed response and continued with Tecentriq® (Figure 3).
- ✔ As of February 2023, patient completed 1 yr of Tecentriq® maintenance with no significant side effects.

IMpower 133

SIGNIFICANT OVERALL SURVIVAL WITH TECENTRIQ® + CARBO/ETOP¹

Updated exploratory survival data based on nearly 2 years of follow-up¹



• Median follow-up: 22.9 months¹

KEY MESSAGE

- ✓ Patients receiving Tecentriq®+carbo/etop had a median **overall survival** of **12.3 months** compared to 10.3 months in the placebo group **hazard ratio = 0.76 (95% CI, 0.60, 0.95)**
- ✓ Patients receiving Tecentriq®+carbo/etop had a median **PFS** of **5.2 months** compared to 4.3 months in the placebo group, **hazard ratio = 0.77 (95% CI, 0.62, 0.96; P=0.0170)**.
- ✓ At the 2-year follow-up, the **overall survival rate was 22%** in the Tecentriq®+carbo/etop group.

References:

1. TECENTRIQ® product information
2. Liu, S.V. E et al. ESMO Abstract AnnOncol. 2020;31;S1032-S133

Disclaimer:

1. © = Registered Trade Mark F. Hoffmann - La Roche Limited, Basel, Switzerland.
2. For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.
3. Full prescribing information available on request
4. For scientific information on Roche Medicinal Product please write to india.medinfo@roche.com
5. For all Adverse Events/Special Situation Reports with Roche Medicinal Product please report the same to india.drugsafety@roche.com within one business day/24 hours



Marketed in India by:
Roche Products (India) Pvt. Ltd.
146-B, 166 A, Unit No. 7, 8, 9; 8th Floor, R City Office, R City Mall,
Lal Bahadur Shastri Marg Ghatkopar, Mumbai, Maharashtra - 400 086;
Tel No. +91 22 50457300; Fax No. +91 22 50457301

Please use the QR code/click on the link for the latest Prescribing Information (PI)



http://bit.ly/Roche_Tecentriq_PI
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

